Skye Bioscience Inc (SKYE)

[cjarmstrong]

Other than the fact that UM is presenting at ICRS, it doesn't seem like there's anything new. UM already presented their normotensive research at AAPS in November, so we already knew NB1111 was effective and safe. I'm sure they have some additional data, but it sounds like it's relevant to the research community and not investors. I wonder if they've tested NB1111 for a more significant length of time (not just 5 days), it would be interesting to know if the cannabinoid receptors in the eye develop a tolerance to THC. Seems like something they should have done already. Anybody know?